Literature DB >> 29861498

Factors Associated to Invasive Fungal Infection in Hispanic Patients with Hematological Malignancies.

Rafael de León-Borrás1, Esteban DelPilar-Morales1, Nicole Rivera-Pérez1, Mara Pallens-Feliciano1, Maribel Tirado-Gómez2, Lorena González-Sepúlveda3, Jorge Bertrán-Pasarell1.   

Abstract

Fungal infections represent a serious complication for immunosuppressed patients resulting in an increased morbidity and mortality. A non-concurrent prospective study was performed to evaluate the factors associated to invasive fungal infection (IFI) in patients with hematological malignancies admitted to the University Hospital in San Juan, Puerto Rico from January 1st, 2011 through June 15th, 2014. The medical records of 84 patients were evaluated. Fifty-nine patients with IFI and twenty-five without IFI. The majority were men between 35 to 55 years old. The main hematological diagnosis was acute myelogenous leukemia (AML) followed by acute lymphoblastic leukemia (ALL). Seventy-percent developed IFI. The most common fungi were C. albicans followed by non-albicans species, Fusarium and, Aspergillus species, respectively. About 63% of the patients with AML and 81% without AML had IFI. Those who received steroids were more likely to develop IFI. After adjusting for AML and age, the odds of IFI among patients using steroids were 3.33 higher than those not using steroids. Patients who were exposed to different antifungal medication had 72% lower odds to develop IFI.

Entities:  

Keywords:  Hematological malignancies; Hispanic; Invasive fungal infection

Mesh:

Substances:

Year:  2017        PMID: 29861498      PMCID: PMC5980240     

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  30 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

3.  Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality.

Authors:  M Weinberger; L Leibovici; S Perez; Z Samra; I Ostfeld; I Levi; E Bash; D Turner; A Goldschmied-Reouven; G Regev-Yochay; S D Pitlik; N Keller
Journal:  J Hosp Infect       Date:  2005-10       Impact factor: 3.926

4.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 6.  Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.

Authors:  E I Boutati; E J Anaissie
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

Review 7.  Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.

Authors:  John R Perfect; Ray Hachem; John R Wingard
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 8.  Empirical antifungal therapy in treating febrile neutropenic patients.

Authors:  John R Wingard
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Candidaemia in patients with haematological disorders and stem cell transplant.

Authors:  Ka Al-Anazi; Am Al-Jasser
Journal:  Libyan J Med       Date:  2006-11-21       Impact factor: 1.657

View more
  1 in total

Review 1.  An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?

Authors:  R G Vitale; J Afeltra; S Seyedmousavi; S L Giudicessi; S M Romero
Journal:  Braz J Microbiol       Date:  2022-03-21       Impact factor: 2.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.